Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Company profile
Ticker
AERI
Exchange
Website
CEO
Vicente Anido
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
203109565
AERI stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
1 Dec 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
8-K
Entry into a Material Definitive Agreement
21 Nov 22
Transcripts
AERI
Earnings call transcript
2022 Q2
7 Aug 22
AERI
Earnings call transcript
2022 Q1
7 May 22
AERI
Earnings call transcript
2021 Q4
25 Feb 22
AERI
Earnings call transcript
2021 Q3
7 Nov 21
AERI
Earnings call transcript
2021 Q2
5 Aug 21
AERI
Earnings call transcript
2021 Q1
6 May 21
AERI
Earnings call transcript
2020 Q4
26 Feb 21
AERI
Earnings call transcript
2020 Q3
8 Nov 20
AERI
Earnings call transcript
2020 Q3
5 Nov 20
AERI
Earnings call transcript
2020 Q2
9 Aug 20
Latest ownership filings
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 54.09 mm | 54.09 mm | 54.09 mm | 54.09 mm | 54.09 mm | 54.09 mm |
Cash burn (monthly) | (no burn) | 646.17 k | 8.91 mm | 2.46 mm | 3.80 mm | (no burn) |
Cash used (since last report) | n/a | 12.16 mm | 167.66 mm | 46.28 mm | 71.51 mm | n/a |
Cash remaining | n/a | 41.93 mm | -113.57 mm | 7.82 mm | -17.42 mm | n/a |
Runway (months of cash) | n/a | 64.9 | -12.7 | 3.2 | -4.6 | n/a |
Institutional ownership, Q1 2023
10.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 37.77 mm |
Total shares | 5.05 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Flynn James E | 4.70 mm | $32.96 mm |
Foresite Capital Fund II | 356.49 k | $4.81 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Nov 22 | Kannan Raj | Common Stock | Sale back to company | Dispose D | No | No | 15.25 | 215,783 | 3.29 mm | 0 |
21 Nov 22 | Kannan Raj | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 6.45 | 197,239 | 1.27 mm | 0 |
21 Nov 22 | Kannan Raj | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 7.14 | 387,169 | 2.76 mm | 0 |
21 Nov 22 | Jeffrey Calabrese | Common Stock | Sale back to company | Dispose D | No | No | 15.25 | 18,585 | 283.42 k | 0 |
21 Nov 22 | Jeffrey Calabrese | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 6.89 | 20,774 | 143.13 k | 0 |
21 Nov 22 | Jeffrey Calabrese | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.23 | 6,257 | 26.47 k | 0 |
21 Nov 22 | Croarkin Richard | Common Stock | Sale back to company | Dispose D | No | No | 15.25 | 16,095 | 245.45 k | 0 |
21 Nov 22 | Croarkin Richard | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 9.14 | 16,854 | 154.05 k | 0 |
21 Nov 22 | Croarkin Richard | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 1.98 | 7,800 | 15.44 k | 0 |
21 Nov 22 | Croarkin Richard | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.81 | 25,000 | 120.25 k | 0 |